Astellas Successfully Concludes Acquisition of Iveric Bio
Astellas Pharma Inc. has completed its acquisition of IVERIC bio, Inc., making it a wholly-owned subsidiary of Astellas. The acquisition was finalized on July 11, 2023, following approval from Iveric Bio's shareholders and regulatory authorities. As a result, Iveric Bio's common stock has been delisted from NASDAQ.
Astellas expressed its satisfaction with the acquisition and
welcomed Iveric Bio as part of the company. The collaboration aims to leverage
the combined capabilities of Astellas and Iveric Bio to benefit millions of
patients suffering from ophthalmologic diseases. The companies are particularly
focused on developing and commercializing differentiated treatments for retinal
diseases, including the potential approval and launch of Avacincaptad Pegol, a
treatment for Geographic Atrophy secondary to Age-Related Macular Degeneration.
Iveric Bio's CEO thanked the outgoing Iveric board and
shareholders for their support and expressed excitement for the company's
future under Astellas. Astellas is currently evaluating the impact of the
acquisition on its consolidated business forecast for the fiscal year ending
March 31, 2024.
Comments
Post a Comment